About Mesa Laboratories, Inc. - Common Stock (MLAB)
Mesa Labs Inc is a global company that specializes in providing advanced technological solutions primarily for the life sciences, healthcare, and industrial sectors. The company develops and manufactures a wide range of products, including instruments, tests, and software that assist in quality control, regulatory compliance, and data management. Mesa Labs focuses on ensuring the integrity and safety of processes and products through innovative solutions that enhance efficiency and accuracy, particularly in areas such as microbial detection, temperature mapping, and sterilization monitoring. Its commitment to research and development allows it to address the evolving needs of its customers and regulatory environments. Read More
LAKEWOOD, Colo., April 07, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 16, 2025, to shareholders of record at the close of business on May 30, 2025.
LAKEWOOD, Colo., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2025 at approximately 8:00 A.M. Eastern time on Tuesday, February 4, 2025.
LAKEWOOD, Colo., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025.
U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
LAKEWOOD, Colo., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024.
LAKEWOOD, Colo., May 31, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 today as previously communicated. The earnings announcement has been delayed as we work to finalize our year end audit which is focused on finalizing the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics and Biopharmaceutical Development divisions and the purchase accounting associated with the acquisition of GKE.
LAKEWOOD, Colo., May 22, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ending March 31, 2024 at approximately 8:00 A.M. Eastern time on Friday, May 31, 2024. Mesa’s Form 10-K will be filed the same day. The earnings announcement has been delayed as we finalize the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics and Biopharmaceutical Development divisions.
Lakewood, Colo., April 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced the closing of its Amended and Restated Credit Agreement (the “Credit Agreement”), which provides up to $200 million of senior secured debt through a syndicate of banks led by JPMORGAN CHASE BANK, N.A. The Credit Agreement includes a $75 million senior secured term loan facility (the “Term Loan”) and a $125 million senior secured revolving credit facility (the “Revolver”), both of which mature in April 2029. The Credit Agreement includes a ten-year amortization schedule and no springing maturity relating to the Company’s 1.375% Convertible Senior Notes due August 2025 (the “2025 Notes”). Both the Term Loan and the Revolver bear interest at a rate of SOFR plus an applicable margin ranging from 1.5% to 3.5%, depending on the Company’s total Net Leverage Ratio. Proceeds from the Term Loan and Revolver will be used to pay down the Company’s 2025 Notes and for normal operating expenditures. The Credit Agreement also allows funds to be used for permitted acquisitions.
LAKEWOOD, Colo., April 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record at the close of business on May 31, 2024.
LAKEWOOD, Colo., April 01, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ending March 31, 2024 at approximately 8:00 A.M. Eastern time on Friday, May 24, 2024.
LAKEWOOD, Colo, March 15, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB, “Mesa” “we” “our” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced the release of its second annual Environmental, Social and Governance ("ESG") Program Brochure. Rooted in Mesa’s unwavering commitment to Protecting the Vulnerable®, this brochure highlights the Company’s continued strides in environmental stewardship, social responsibility, and corporate governance.
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is estimated to report quarterly earnings at $0.26 per share on revenue of $43.92 million.
LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, today announced the appointment of Mark Capone to its Board of Directors (the “Board”), effective January 5, 2024.
LAKEWOOD, Colo. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that on January 2, 2024 its Board of Directors declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2024, to shareholders of record at the close of business on February 29, 2024.
LAKEWOOD, Colo., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us” or “our”), a global leader in the design and manufacturing of life science tools and critical quality control solutions, announced the completed acquisition of GKE-GmbH’s sterilization indicators business and its accredited, independent testing lab SAL GmbH on October 16th, 2023. Today, Mesa announced the completion of the acquisition of GKE’s Chinese sales entity, Beijing GKE Science & Technology Co. LTD (“GKE China”) effective December 31, 2023, which completes all related transactions. Together, the entities are referred to as “GKE.”
LAKEWOOD, Colo., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2024 at approximately 8:00 A.M. Eastern time on Monday, February 5, 2024.
